RT Journal Article
T1 IGF1R as a Potential Pharmacological Target in Allergic Asthma
A1 Alfaro Arnedo, Elvira
A1 López, Icíar P.
A1 Piñeiro Hermida, Sergio
A1 Ucero Herrería, Álvaro Conrado
A1 Gonzalez Barcala, Francisco Javier
A1 Salgado, Francisco Javier
A1 Pichel, José G.
AB Background: Asthma is a chronic lung disease characterized by reversible airflow obstruction, airway hyperresponsiveness (AHR), mucus overproduction and inflammation. Although Insulin-like growth factor 1 receptor (IGF1R) was found to be involved in asthma, its pharmacological inhibition has not previously been investigated in this pathology. We aimed to determine if therapeutic targeting of IGF1R ameliorates allergic airway inflammation in a murine model of asthma. Methods: C57BL/6J mice were challenged by house dust mite (HDM) extract or PBS for four weeks and therapeutically treated with the IGF1R tyrosine kinase inhibitor (TKI) NVP-ADW742 (NVP) once allergic phenotype was established. Results: Lungs of HDM-challenged mice exhibited a significant increase in phospho-IGF1R levels, incremented AHR, airway remodeling, eosinophilia and allergic inflammation, as well as altered pulmonary surfactant expression, all of being these parameters counteracted by NVP treatment. HDM-challenged lungs also displayed augmented expression of the IGF1R signaling mediator p-ERK1/2, which was greatly reduced upon treatment with NVP. Conclusions: Our results demonstrate that IGF1R could be considered a potential pharmacological target in murine HDM-induced asthma and a candidate biomarker in allergic asthma.
PB MDPI
SN 2227-9059
YR 2021
FD 2021-07-24
LK https://hdl.handle.net/20.500.14352/5052
UL https://hdl.handle.net/20.500.14352/5052
LA eng
NO Correction published on 22 March 2022, see Biomedicines 2022, 10(4), 733.
NO Unión Europea
NO Ministerio de Ciencia e Innovación (España)
NO Fundación Rioja Salud (Gobierno de La Rioja)
DS Docta Complutense
RD 10 abr 2025